T2D and CV Risk Reduction: Future Management

June 12, 2019 12:51 pm

Future considerations for managing patients with type 2 diabetes and associated cardiovascular risk based on emerging data and clinical recommendations with SGLT2 inhibitors and GLP-1 agonists.

Category: News
About The Author
-
Previous

Hua Medicine – A Global Effort to Stop Diabetes
Next

EASD 2019 : Personalised Prevention Of CVD In T2D- Prof Alessandro Doria

Related Videos

Medication-adherence-in-Malaysian-patients-with-T2D-Video-abstract-81612

Medication adherence in Malaysian patients with T2D – Video abstract 81612

Top-health-insurer-to-launch-a-program-for-controlling-T2D

Top health insurer to launch a program for controlling T2D

Preview-A-low-carb-diet-for-T2D-reversal-Dr.-Sarah-Hallberg

[Preview] A low-carb diet for T2D reversal – Dr. Sarah Hallberg

Unleashing-the-Truth-Approaching-T2D-Treatment-as-a-Team-Sport

Unleashing the Truth: Approaching T2D Treatment as a Team Sport

Type-2-Diabetes-Dr-Stephen-Hull-Practical-Advice-for-People-with-T2D-and-Heart-Disease

Type 2 Diabetes: Dr Stephen Hull – Practical Advice for People with T2D and Heart Disease

Sodium-Glucose-Transporter-2-Inhibition-An-Important-Advancement-for-Patients-with-T2D-and-CKD

Sodium-Glucose Transporter-2 Inhibition: An Important Advancement for Patients with T2D and CKD